SC1: Targeting the Cancer Mutanome - Detailed Agenda

Laszlo Radvanyi, Ph.D., Senior Vice President; Head of Immuno-Oncology Translational Innovation Platform (TIP), EMD Serono

Luis M. Vence, Ph.D., Scientific Manager, Immunology, MD Anderson Cancer Center

Alena Gros Vidal, Ph.D., Principal Investigator, Tumor Immunology and Immunotherapy, Vall d’Hebron Institute of Oncology (VHIO), Spain

Suchit Jhunjhunwala, Ph.D., Scientist, Bioinformatics, Genentech

Emerging sequencing and bioinformatics technologies are now giving researchers new perspectives on the mutations in patient specific antigens, now collectively known as the cancer mutanome. Our dinner short course offers academic and industry perspectives on the analytical and computational methods used to identify neo-epitopes within a mutanome that are candidates for therapeutic intervention – and the potential applications of this knowledge in patient diagnostics and immunotherapy. An open discussion format will allow those working in this space to share insights and experiences on how to advance this new field into clinical practice.

SC2: Bispecific Antibody Development for Immunotherapy - Detailed Agenda

Sanja Gauthier, M.D., Senior Medical Director, Medical Safety Evaluation, Pharmacovigilance and Patient Safety, AbbVie

Cris Kamperschroer, Ph.D., Associate Research Fellow, Drug Safety R&D, Pfizer

Bispecific molecules designed to recruit T cells and induce them to kill tumor cells are showing promise as cancer immunotherapies. There are challenges to developing these molecules, including safety concerns related to the intended pharmacology of T cell activation. This presentation will cover the nonclinical development of a specific T cell targeting bispecific molecule, its key safety concerns, and approaches to mitigate the concerns.

This short course will address: